Drug Profile
Ciclosporin - Novartis
Alternative Names: Ciclosporin microemulsion - Novartis; Cyclosporin A microemulsion - Novartis; Cyclosporin microemulsion - Novartis; Cyclosporin modified - Novartis; Cyclosporine microemulsion - Novartis; Neoral; OLO400; Sandimmun Neoral; Sandimmune NeoralLatest Information Update: 07 Nov 2021
Price :
$50
*
At a glance
- Originator Novartis
- Developer Erasmus MC; Novartis
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
- Mechanism of Action Calcineurin inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Atopic dermatitis; Heart transplant rejection; Liver transplant rejection; Myasthenia gravis; Pancreas transplant rejection; Psoriasis; Renal transplant rejection; Rheumatoid arthritis; Transplant rejection
- Discontinued Ulcerative colitis
Most Recent Events
- 12 Jul 2016 No development reported - Phase-I for Psoriasis in Netherlands (Topical)
- 30 Jul 2014 Discontinued - Phase-II for Ulcerative colitis in England (PO)
- 30 Sep 2007 Preregistration for Atopic dermatitis in Japan (PO)